Phase I
Phase II
Phase III
Oncology
MIDD
Trial design and analysis
Pharmacometrics
Program strategies and efficiencies
PAGE 33 (2025) Abstr 11666
Zdovc JA, Gausi K, Langenhorst J, Yin A, Acharya C, Sarr C, Friberg LE, Lahmar M, Grempler R, Pérez-Pitarch A, Schmid U, LoRusso P, Sailer R, Busse D.